Damping of electromagnetic waves due to electron-positron pair production

The problem of the backreaction during the process of electron-positron pair production by a circularly polarized electromagnetic wave propagating in a plasma is investigated. A model based on the relativistic Boltzmann-Vlasov equation with a source term corresponding to the Schwinger formula for the pair creation rate is used. The damping of the wave, the nonlinear up-shift of its frequency due to the plasma density increase and the effect of the damping on the wave polarization and on the background plasma acceleration are investigated as a function of the wave amplitude.Comment: 11 pages, 5 figures; revtex

Quantum simulator for the Schwinger effect with atoms in bi-chromatic optical lattices

Ultra-cold atoms in specifically designed optical lattices can be used to mimic the many-particle Hamiltonian describing electrons and positrons in an external electric field. This facilitates the experimental simulation of (so far unobserved) fundamental quantum phenomena such as the Schwinger effect, i.e., spontaneous electron-positron pair creation out of the vacuum by a strong electric field.Comment: 4 pages, 2 figures; minor corrections and improvements in text and in figures; references adde

Back-Reaction In Lightcone QED

We consider the back-reaction of quantum electrodynamics upon an electric field E(x_+) = - A'_-(x_+) which is parallel to x^3 and depends only on the lightcone coordinate x_+ = (x^0 + x^3)/\sqrt{2}. Novel features are that the mode functions have simple expressions for arbitrary A_-(x_+), and that one cannot ignore the usual lightcone ambiguity at zero + momentum. Each mode of definite canonical momenta k_+ experiences pair creation at the instant when its kinetic momentum p_+=k_+ - e A_-(x_+) vanishes, at which point operators from the surface at x_- =-\infty play a crucial role. Our formalism permits a more explicit and complete derivation of the rate of particle production than is usually given. We show that the system can be understood as the infinite boost limit of the analogous problem of an electric field which is homogeneous on surfaces of constant x^0.Comment: 37 pages, 2 figures, LaTeX 2 epsilo

Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival

In obesity, beta cells activate compensatory mechanisms to adapt to the higher insulin demand. Interleukin-1 receptor antagonist (IL-1Ra) prevents obesity-induced hyperglycaemia and is a potent target for the treatment of diabetes, but the mechanisms of its secretion and regulation in obesity are unknown. In the present study, we hypothesise the regulation of IL-1Ra secretion by purinergic P2X7 receptors in islets. Production and regulation of P2X7 were studied in pancreatic sections from lean and obese diabetic patients, non-diabetic controls and in isolated islets. IL-1Ra, IL-1β and insulin secretion, glucose tolerance and beta cell mass were studied in P2x7 (also known as P2Rx7)-knockout mice. P2X7 levels were elevated in beta cells of obese patients, but downregulated in patients with type 2 diabetes mellitus. Elevated glucose and non-esterified fatty acids rapidly activated P2X7 and IL-1Ra secretion in human islets, and this was inhibited by P2X7 blockade. In line with our results in vitro, P2x7-knockout mice had a lower capacity to secrete IL-1Ra. They exhibited severe and rapid hyperglycaemia, glucose intolerance and impaired beta cell function in response to a high-fat/high-sucrose diet, were unable to compensate by increasing their beta cell mass in response to the diet and showed increased beta cell apoptosis. Our study shows a tight correlation of P2X7 activation, IL-1Ra secretion and regulation of beta cell mass and function. The increase in P2X7 production is one mechanism that may explain how beta cells compensate by adapting to the higher insulin demand. Disturbances within that system may result in the progression of diabetes

Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.

Preliminary evidence has associated testosterone and prostate-specific antigen (PSA) with breast cancer. Our objective was to determine whether a) testosterone levels in nipple aspirate fluid (NAF), serum, or breast tissue are associated with breast cancer; b) testosterone levels in serum are associated with levels in NAF; c) PSA in NAF, serum, or breast tissue is associated with breast cancer; and d) serum PSA is associated with NAF PSA levels. We obtained 342 NAF specimens from 171 women by means of a modified breast pump. Additionally, we collected 201 blood samples from 99 women and 51 tissue samples from 41 subjects who underwent surgical resection for suspected disease. Women currently using birth control pills or hormone replacement therapy were excluded from the study. Controlling for age and menopausal status, serum testosterone was significantly increased in women with breast cancer (p = 0.002). NAF and serum testosterone levels were not associated. Neither NAF nor tissue testosterone was associated with breast cancer. Controlling for menopausal status and age, NAF PSA was significantly decreased in women with breast cancer (p \u3c 0.001). We did not find serum PSA to be associated with breast cancer, although we found an indication that, in postmenopausal women, its levels were lower in women with cancer. Serum PSA was associated with NAF PSA in postmenopausal women (p \u3c 0.001). PSA levels in cancerous tissue were significantly lower than in benign breast specimens from subjects without cancer (p = 0.011), whereas levels of PSA in histologically benign specimens from subjects with cancer were intermediate. Our results suggest that serum testosterone is increased and NAF PSA is decreased in women with breast cancer, with PSA expression being higher in normal than in cancerous breast tissues. NAF and serum PSA levels in postmenopausal women are correlated, suggesting that as laboratory assessment of PSA becomes more sensitive, serum PSA may become useful in identifying women with breast cancer

Dynamically assisted Schwinger mechanism

We study electron-positron pair creation {from} the Dirac vacuum induced by a strong and slowly varying electric field (Schwinger effect) which is superimposed by a weak and rapidly changing electromagnetic field (dynamical pair creation). In the sub-critical regime where both mechanisms separately are strongly suppressed, their combined impact yields a pair creation rate which is {dramatically} enhanced. Intuitively speaking, the strong electric field lowers the threshold for dynamical particle creation -- or, alternatively, the fast electromagnetic field generates additional seeds for the Schwinger mechanism. These findings could be relevant for planned ultra-high intensity lasers.Comment: 4 pages, 2 figure

Oscillatory Energy Exchange Between Waves Coupled by a Dynamic Artificial Crystal

We describe a general mechanism of controllable energy exchange between waves propagating in a dynamic artificial crystal. We show that if a spatial periodicity is temporarily imposed on the transmission properties of a wave-carrying medium whilst a wave is inside, this wave is coupled to a secondary counter-propagating wave and energy oscillates between the two. The oscillation frequency is determined by the width of the spectral band gap created by the periodicity and the frequency difference between the coupled waves. The effect is demonstrated with spin waves in a dynamic magnonic crystal.Comment: 5 pages, 4 figure

Double diffractive meson production and the BFKL Pomeron at e+e−e^+e^- colliders

In this Letter we study the double diffractive vector meson production in $e^+e^-$ collisions assuming the dominance of the BFKL pomeron exchange. We consider the non-forward solution of the BFKL equation at high energy and large momentum transfer and estimate the total cross section for the process $e^+e^- \to e^+e^- V_1 V_2$ with antitagged $e^+$ and $e^-$, where $V_1$ and $V_2$ can be any two vector mesons ($V_i = \rho, \omega, \phi, J/\Psi, \Upsilon$). The event rates for the future linear colliders are given.Comment: 8 pages, 1 figure, Version to be published in Physical Review

Convergence analysis of a multigrid algorithm for the acoustic single layer equation

We present and analyze a multigrid algorithm for the acoustic single layer equation in two dimensions. The boundary element formulation of the equation is based on piecewise constant test functions and we make use of a weak inner product in the multigrid scheme as proposed in \cite{BLP94}. A full error analysis of the algorithm is presented. We also conduct a numerical study of the effect of the weak inner product on the oscillatory behavior of the eigenfunctions for the Laplace single layer operator

Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase.

Background: Fruquintinib (Fruq) is a potent, highly selective, novel vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor. In the Phase III FRESCO trial1 that led to the drug approval in China, Fruq improved the median overall survival in patients with metastatic colorectal cancer (mCRC) in the third line or later setting when compared to placebo (9.3 vs 6.6 months); hazard ratio 0.65 (95% CI, 0.51-0.83; P \u3c .001), Methods: This is a Phase 1 open-label, dose escalation/dose expansion study conducted in the US (NCT03251378). The primary objectives are to evaluate the safety and tolerability of Fruq in pts with advanced solid tumors and to determine the recommended phase 2 dose (RP2D). A secondary objective is to evaluate anticancer activity. There were 2 dose cohorts: 3mg and 5 mg qd, each on a 3 weeks on, 1 week (3/1) off schedule. Results: Fourteen pts were enrolled: 7 (6 evaluable) pts in each dose cohort. Fruq was generally well-tolerated. There was 1 dose-limiting toxicity (DLT) of grade 4 hypertension in the 3 mg cohort, and no DLTs in the 5 mg cohort. The RP2D was 5 mg qd (3/1), which is also the approved dose in China. Two other serious adverse events were reported: colon obstruction and left breast cellulitis; neither was suspected to be drug-related. All 14 pts reported AEs; the most common were vomiting (57%), nausea (50%), constipation (50%, proteinuria (50%), hypertension (50%), dysphonia (43%), anorexia (36%), and dyspepsia (36%). Ten pts were evaluable for best objective response; results were partial response 3, stable disease 6, and disease progression 1. Objective response rate was 3/14 (21.4%) and disease control rate was 9/14 (64.3%). Mean duration on study drug was 5.3 months. Conclusion: Fruq is generally well-tolerated in heavily pretreated patients. The RP2D in US pts is 5 mg qd (3/1). The safety profile is consistent with that of other anti-angiogenic tyrosine kinase inhibitors. There is preliminary evidence of anticancer activity in pts with advanced solid tumors. The dose expansion phase of the study is ongoing. Further investigation of Fruq in pts with mCRC is planned. 1. JAMA 2018; 319:2486